title: [Clinical meaning of EML4-ALK fusion gene in non-small cell lung cancer].
abstract: Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In recent years, more and more attention has been focused on some new molecular targets in NSCLC, such as echinodem microtubule-associated protein-like4/anaplastic lymphoma kinase (EML4-ALK) fusion gene. This review will focus on the basic structure, clinicopathologic features, detection method, ALK inhibitor and therapeutic meaning of EML4-ALK in NSCLC.
authors: Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China. 378086283@qq.com
authors: Wei
authors: W
authors: Han
authors: Minghong
authors: M
authors: Bi
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors